ranibizumab + ranibizumab
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Central Retinal Vein Occlusion
Conditions
Central Retinal Vein Occlusion, Macular Edema
Trial Timeline
Mar 1, 2007 → Oct 1, 2008
NCT ID
NCT00567697About ranibizumab + ranibizumab
ranibizumab + ranibizumab is a phase 3 stage product being developed by Novartis for Central Retinal Vein Occlusion. The current trial status is completed. This product is registered under clinical trial identifier NCT00567697. Target conditions include Central Retinal Vein Occlusion, Macular Edema.
What happened to similar drugs?
4 of 19 similar drugs in Central Retinal Vein Occlusion were approved
Approved (4) Terminated (2) Active (13)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00567697 | Phase 3 | Completed |
Competing Products
20 competing products in Central Retinal Vein Occlusion